Brown Advisory Inc. Has $19.43 Million Position in Agios Pharmaceuticals, Inc. (AGIO)
Brown Advisory Inc. lifted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 8.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 291,139 shares of the biopharmaceutical company’s stock after buying an additional 22,736 shares during the period. Brown Advisory Inc. owned about 0.60% of Agios Pharmaceuticals worth $19,433,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in AGIO. Teachers Advisors LLC boosted its position in shares of Agios Pharmaceuticals by 2.3% during the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Agios Pharmaceuticals by 9.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 83,327 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 7,158 shares during the last quarter. Aperio Group LLC purchased a new position in Agios Pharmaceuticals in the second quarter worth $206,000. Public Employees Retirement Association of Colorado boosted its position in Agios Pharmaceuticals by 5.2% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 323 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in Agios Pharmaceuticals by 9.7% in the second quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 425 shares during the last quarter. 94.28% of the stock is currently owned by institutional investors.
In other news, insider Scott Biller sold 15,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $65.00, for a total transaction of $975,000.00. Following the transaction, the insider now owns 6,264 shares of the company’s stock, valued at approximately $407,160. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $60.88, for a total value of $243,520.00. Following the transaction, the director now directly owns 82,394 shares in the company, valued at approximately $5,016,146.72. The disclosure for this sale can be found here. Insiders have sold a total of 170,762 shares of company stock worth $11,657,608 in the last ninety days. Insiders own 5.43% of the company’s stock.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. During the same quarter in the prior year, the firm earned ($1.63) EPS. The business’s revenue for the quarter was up 26.4% compared to the same quarter last year. sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current year.
AGIO has been the topic of several research analyst reports. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective on the stock. Credit Suisse Group boosted their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks reissued a “buy” rating and issued a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $75.70.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.